Case Number 7571
Request Date 30/09/2020
Completion Date 23/02/2021

 

Details of the Request

1. How many patients have been treated with the following drugs (for any disease) in the past 6 months:

  • Ampyra (dalfampridine)
  • Aubagio (teriflunomide)
  • Avonex (interferon beta-1a)
  • Betaferon (interferon beta-1b)
  • Brabio (glatiramer acetate)
  • Copaxone (glatiramer acetate)
  • Extavia (beta interferon-1b)
  • Gilenya (fingolimod)
  • Lemtrada (alemtuzumab)
  • Mavenclad (cladribine)
  • Mayzent (siponimod)
  • Ocrevus (ocrelizumab)
  • Plegridy (peginterferon beta-1a)
  • Rebif (beta interferon-1a)
  • Tecfidera (dimethyl fumarate)
  • Tysabri (natalizumab)
  • Vumerity (diroximel fumarate)
  • Zeposia (ozanimod)

 

2. How many patients have been treated in the past 6 months for the following types of multiple sclerosis:

  • Relapsing remitting MS (RRMS)
  • Secondary progressive MS (SPMS)
  • Primary progressive MS (PPMS)
  • Multiple Sclerosis - any type

 

Details of the Response

How many patients have been treated with the following drugs (for any disease) in the past 6 months:

Data for 6 months to 19/2/21

Ampyra (dalfampridine) 0
Aubagio (teriflunomide) 15
Avonex (interferon beta-1a) 5
Betaferon (interferon beta-1b) 0
Brabio (glatiramer acetate) 25
Copaxone (glatiramer acetate) 2
Extavia (beta interferon-1b) 0
Gilenya (fingolimod) 32
Lemtrada (alemtuzumab) 0
Mavenclad (cladribine) 4
Mayzent (siponimod) 0
Ocrevus (ocrelizumab) 9
Plegridy (peginterferon beta-1a) 3
Rebif (beta interferon-1a) 17
Tecfidera (dimethyl fumarate) 62
Tysabri (natalizumab) 22
Vumerity (diroximel fumarate) 0
Zeposia (ozanimod) 0

 

2. How many patients have been treated in the past 6 months for the following types of multiple sclerosis:

Data for 6 months to 19/2/21

Relapsing remitting MS (RRMS) 204
Secondary progressive MS (SPMS) 204
Primary progressive MS (PPMS) 0
Multiple Sclerosis - any type 0

 

 

Protecting Your Online Privacy
Protecting Your Online Privacy

This Ashford and St Peter's website uses cookies to track visitor numbers. Find out more in our Cookies Policy and Privacy Policy. You can also read our Accessibility Statement and Privacy Notice for your information.